2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1397

Correlation and Responsiveness of Cutaneous Lupus Disease Area and Severity Index (CLASI) and Skindex-29 with Cutaneous Childhood Lupus Erythematosus (cSLE)
Abstract Number: 343

Correlation Between Metacarpal Cortical Bone Mineral Density Measured By Dual X-Ray Densitometry and Radiogrammetry on Early Arthritis Patients
Abstract Number: 728

Correlation Between the Spinal MRI Findings and the Serum Level of DKK-1 in Patients with Spondyloarthritis Treated with TNF Antagonist
Abstract Number: 1356

Correlation of Erythrocyte Sedimentation Rate with Glycohemoglobin Values and Other Patient Factors
Abstract Number: 1011

Correlations Between B Cell Epitope Specificity and Clinical Features in Patients with Jo-1 Antibodies and the Anti-Synthetase Syndrome
Abstract Number: 326

Cortical Bone Changes in Pre- and Postmenopausal Healthy Women Measured with HR-pQCT
Abstract Number: 253

Corticosteroid-Free Tocilizumab Monotherapy for Adult Onset Still’s Disease: Results in Six Month
Abstract Number: 1515

Could Increase Levels of Dickkopf-1 Protein be Considered As a Potential Biomarker for Bone Resorption in Joint and Periodontal Disease in Patients with Early Rheumatoid Arthritis?
Abstract Number: 2435

Counseling on Family Planning and Contraception, and Pregnancy Outcome in Women with Rheumatic Diseases: Analysis of 398 Patient-Reported Questionnaires from a Multicenter Italian Study
Abstract Number: 1090

CpG-Stimulated B Cells Require Glutaminolysis for Glycolysis, Mitochondrial Respiration, and Cytokine Production
Abstract Number: 2262

CR6086 a New Potent EP4 Receptor Antagonist with Immunomodulatory Activities
Abstract Number: 1972

Creatine Kinase in the United States Population: Impact of Demographics, Comorbidities and Body Composition on the Normal Range
Abstract Number: 308

Crepitus As a Risk Factor for Symptomatic Knee Osteoarthritis: Data from the Osteoarthritis Initiative
Abstract Number: 2869

Critical Roles of IRAK4 Kinase Activity in Inflammation but Not B Cell Response in SLE
Abstract Number: 448

Cross-Cultural and Construct Validity of the Animated Activity Questionnaire to Assess Activity Limitations in Patients with Hip and Knee Osteoarthritis in Different Languages

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].